INTERIM REPORT JANUARY - MARCH 2005

• Biacore’s first quarter sales showed strong recovery increasing by 22% to SEK 116.0 million (95.4). Sales in Asia-Pacific grew by 236% due to the continuing recovery in the important Japanese market and increased demand from emerging markets such as China. The growth in Asia-Pacific more than offset lower sales in Europe and the Americas. Excluding the effect of exchange rates, total sales increased by 26%. • Operating income for the first quarter rebounded strongly to SEK 13.9 million (-1.4) due to the much improved sales figure and lower R&D spending. • Net income for the first quarter amounted to SEK 12.0 million (-1.0). Diluted earnings per share were SEK 1.24 (-0.08). • Biacore extended its leading global position in the field of protein interaction analysis with the launch of Biacore®T100 in February. The market reception to this new system has been very positive. • Biacore’s product line was extended further in March with the acquisition of FLEXChip System and technology from HTS BioSystems Inc. This acquisition is in line with Biacore’s strategy of looking for complementary external growth opportunities. • In February, Biacore appointed Mr. Terry Pizzie as Senior Vice President of Commercial Operations. • Biacore maintains its previous outlook for the full-year 2005: Biacore anticipates achieving an increase in sales and returning to historic levels of profitability with variations between the quarters. • As from January 1, 2005, Biacore uses IFRS (International Financial Reporting Standards). Prior year amounts have been restated accordingly. For further information, please contact: Erik Walldén, President and CEO, Phone +41 (0)79 769 4542 Lars-Olov Forslund, CFO, Phone +41 (0)79 347 9900 Jan Isoz, Investor Relations, Phone +46 (0)708 10 31 17